Streetbeat News

Analyst Ratings

CACI

Truist Securities analyst Tobey Sommer has maintained a 'Buy' rating on CACI International (NYSE:CACI) and raised the price target from $345 to $385.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:58 pm

STRO

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Sutro Biopharma (NASDAQ:STRO) and maintained a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 4:58 pm

TAST

Truist Securities analyst Jake Bartlett maintains a 'Buy' rating on Carrols Restaurant Group (NASDAQ:TAST) and has raised the price target from $7 to $9.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:57 pm

LQDA

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Liquidia (NASDAQ:LQDA) and maintained a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 4:57 pm

AMLX

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Amylyx Pharma (NASDAQ:AMLX) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 4:56 pm

PBLA

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Panbela Therapeutics (NASDAQ:PBLA) and maintained a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 4:56 pm

AL

Citigroup analyst Kevin Crissey maintains a Neutral rating on Air Lease (NYSE:AL) and raises the price target from $41 to $43.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:56 pm

MOGO

HC Wainwright & Co. analyst Scott Buck has reiterated a 'Buy' rating on Mogo (NASDAQ:MOGO) and maintained a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 4:55 pm

DNUT

Citigroup analyst Sergio Matsumoto has maintained a Neutral rating on Krispy Kreme (NASDAQ:DNUT) and lowered the price target from $17 to $15.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 4:54 pm

ABT

BSX

JNJ

MDT

Boston Scientific Corp (BSX) is set to present results from its ADVENT pivotal trial for the Farapulse Pulsed Field Ablation (PFA) system at the 2023 European Society of Cardiology Congress. The trial compares Farapulse to standard-of-care RF ablation and cryoballoon ablation. Analysts from Needham believe the trial could support FDA approval for Farapulse. The global electrophysiology market, valued at $7.6 billion in 2022, is projected to reach $9.4 billion by 2024. Boston Scientific's electrophysiology operations currently contribute about 5% of its revenue.

Portfolio Pulse from Vandana Singh

August 11, 2023 | 4:53 pm